➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Last Updated: October 23, 2020

DrugPatentWatch Database Preview

Ocriplasmin - Biologic Drug Details

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for ocriplasmin

Tradenames:	1
Patents:	8
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for ocriplasmin

Recent Clinical Trials for ocriplasmin

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Wagner Macula & Retina Center	Phase 2
Katholieke Universiteit Leuven	Phase 1
Universitaire Ziekenhuizen Leuven	Phase 1

See all ocriplasmin clinical trials

Pharmacology for ocriplasmin

Ingredient-type	Peptide Hydrolases

Company Disclosures: US Patents for ocriplasmin

These patents were extracted from company disclosures

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Number	Approval Date	Patent No.	Assignee	Estimated Patent Expiration	Status	Orphan	Source
Thrombogenics, Inc	JETREA	ocriplasmin	INJECTABLE; INTRAVITREAL	125422	001	2012-10-17	Start Trial	Thromb-X nv (Leuven, BE)	2020-12-21	RX		company
Thrombogenics, Inc	JETREA	ocriplasmin	INJECTABLE; INTRAVITREAL	125422	001	2012-10-17	Start Trial	ThromboGenics NV (Leuven, BE)	2022-12-06	RX		company
Thrombogenics, Inc	JETREA	ocriplasmin	INJECTABLE; INTRAVITREAL	125422	001	2012-10-17	Start Trial	ThromboGenics NV (Heverlee, BE)	2022-12-06	RX		company
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Number	>Approval Date	>Patent No.	>Assignee	>Estimated Patent Expiration	>Status	>Orphan	>Source

Patent Text Search: US Patents for ocriplasmin

These patents were identified by searching patent claims

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Number	Approval Date	Patent No.	Assignee	Estimated Patent Expiration	Status	Orphan	Source
Thrombogenics, Inc	JETREA	ocriplasmin	INJECTABLE; INTRAVITREAL	125422	001	2012-10-17	Start Trial	OcuJect, LLC (Newport Beach, CA)	2032-04-02	RX		search
Thrombogenics, Inc	JETREA	ocriplasmin	INJECTABLE; INTRAVITREAL	125422	001	2012-10-17	Start Trial	Corning Incorporated (Corning, NY)	2031-10-25	RX		search
Thrombogenics, Inc	JETREA	ocriplasmin	INJECTABLE; INTRAVITREAL	125422	001	2012-10-17	Start Trial	OcuJect, LLC (Newport Beach, CA)	2032-04-02	RX		search
Thrombogenics, Inc	JETREA	ocriplasmin	INJECTABLE; INTRAVITREAL	125422	001	2012-10-17	Start Trial	OcuJect, LLC (Newport Beach, CA)	2032-04-02	RX		search
Thrombogenics, Inc	JETREA	ocriplasmin	INJECTABLE; INTRAVITREAL	125422	001	2012-10-17	Start Trial	Wayne State University (Detroit, MI)	2033-03-14	RX		search
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Number	>Approval Date	>Patent No.	>Assignee	>Estimated Patent Expiration	>Status	>Orphan	>Source

International Patents for ocriplasmin

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
Japan	5996026	Start Trial
Austria	534400	Start Trial
European Patent Office	2968476	Start Trial
United Kingdom	0228409	Start Trial
Spain	2296705	Start Trial
>Country	>Patent Number	>Estimated Expiration

Supplementary Protection Certificates for ocriplasmin

Subscribe to access the full database, or Start Trial
Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
90041-0	Sweden	Start Trial	MARKNADSGODKAENNANDE NR.: EU/1/13/819/001, 2013-03-15, MIKROPLASMIN
1232252/01	Switzerland	Start Trial	PRODUCT NAME: OCRIPLASMINUM; REGISTRATION NO/DATE: SWISSMEDIC 63053 13.03.2014
C0052	France	Start Trial	PRODUCT NAME: MICROPLASMINE; REGISTRATION NO/DATE: EU/1/13/819/001 20130315
13C/055	Belgium	Start Trial	DETAILS ASSIGNMENT: CHANGE OF OWNER(S), CHANGEMENT DE NOM DU PROPRIETAIRE
2013020,C1581254	Lithuania	Start Trial	PRODUCT NAME: OCRIPLASMINUM (MICROPLASMINUM); REGISTRATION NO/DATE: EU/1/13/819/001 20130313
>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts

Harvard Business School

Dow

Mallinckrodt

McKinsey

AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

By using our website you are consenting to our use of cookies in accordance with our privacy policy.